Program
Please note that this meeting will take place as an in-person event in Bellevue and will not live-stream content for virtual participation. The meeting content will be recorded and made available as an on-demand program after the conference. Please see the registration page for details.
CME credit is available for in-person attendance for the designated sessions. On-demand presentations are not eligible for CME.
All presentations are scheduled to be live, in-person presentations at the date and time specified below unless noted otherwise. Program in progress.
*-Short talk from proffered abstract
THURSDAY, NOVEMBER 14
FRIDAY, NOVEMBER 15
- Plenary Session 1: Deregulation of RNA in Cancer
- Plenary Session 2: Design of mRNA Drugs
- Plenary Session 3: Interaction between RNA Drugs and the Immune System
SATURDAY, NOVEMBER 16
- Plenary Session 4: RNA Delivery
- Plenary Session 5: RNAs as Drivers and Targets in Cancer
- Plenary Session 6: Small RNA Therapeutics
SUNDAY, NOVEMBER 17
Registration
6-7 p.m. | Evergreen Ballroom Foyer
WELCOME AND OPENING KEYNOTE
6-7 p.m. | Evergreen E-F | CME Eligible
- 6 p.m. | Welcome from Conference Cochairs
- 6:05 p.m. | Keynote Lecture
Davide Ruggero, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California
Opening Reception
7-8:30 p.m. | Evergreen A-D
Continental Breakfast
7-8 a.m. | Evergreen A-D
Plenary Session 1: Deregulation of RNA in cancer
8-10 a.m. | Evergreen E-F | CME Eligible
Session Chair: Hani Goodarzi, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California
- 8 a.m. | Systematic discovery and annotation of cancer emergent orphan non-coding RNAs in human cancers
Hani Goodarzi - 8:30 a.m. | Alternative polyadenylation as a therapeutic target in cancer
Robert Bradley, Fred Hutchinson Cancer Center, Seattle, Washington - 9 a.m. | Decoding regulators of lineage infidelity gene programs in classic Hodgkin lymphoma
Anna Nam, Weill Cornell Medicine, New York, New York - 9:30 a.m. | Targeting RNA methyltransferase in cancer therapy*
Li Lan, Harvard Medical School/Massachusetts General Hospital, Boston, Massachusetts - 9:45 a.m. | Epigenetic coordination of transcriptional and translational programs in hypoxia*
Ola Larsson, Karolinska Institutet, Solna, Sweden
Plenary Session 2: Design of mRNA drugs
10:30 a.m. – 12:30 p.m. | Evergreen E-F | CME Eligible
Session Chair: Narry Kim, Seoul National University, Seoul, Korea
- 10:30 a.m.
Giles Besin, Orbital Therapeutics, Cambridge, Massachusetts - 11 a.m. | The role of RNA processing in cancer progression – from basic mechanisms to cancer therapy
Rotem Karni, Hebrew University-Hadassah Medical School, Jerusalem, Israel - 11:30 a.m.
Narry Kim - 12 p.m. | mRNA tumor vaccines: advantages and challenges*
- William Jia, Virogin Biotech, Vancouver, BC, Canada
- 12:15 p.m.*
Ross Hannan, Australian National University, Canberra, Australia
Lunch Break on own
12:30-2:30 p.m.
Plenary Session 3: Interaction between RNA drugs and the immune system
2:30-4:30 p.m. | Evergreen E-F | CME Eligible
Session Chair: Sun Hur, Harvard Medical School, Boston, Massachusetts
- 2:30 p.m. | Regulation of cellular response to endogenous dsRNA
Sun Hur - 3 p.m. | Double stranded RNAs in cancer therapeutics
Yoosik Kim, Korea Advanced Institute of Science and Technology, Daejeon, South Korea - 3:30 p.m.
Serena Silver, Accent Therapeutics, Boston, Massachusetts - 4 p.m. | Modulating the immunosuppressive pancreas tumor microenvironment through intratumoral delivery of cytokine encoding mRNAs*
Chaitanya Naimesh Parikh, University of Massachusetts Medical School, Worcester, Massachusetts - 4:15 p.m. | Target validation and drug discovery for exoribonuclease XRN1*
P. Ann Boriack-Sjodin, Accent Therapeutics, Lexington, Massachusetts
Poster Session A (with light refreshments)
4:30-7 p.m. | Evergreen A-D
Continental Breakfast
7-8 a.m. | Evergreen A-D
Plenary Session 4: RNA delivery
8-10 a.m. | Evergreen E-F | CME Eligible
Session Chair: Howard Chang, Stanford University, Stanford, California
- 8 a.m. | Small RNAs as guardians of genome integrity
Gregory J. Hannon, University of Cambridge, Cambridge, UK - 8:30 a.m. | Leveraging engineered virus-like particles for protein and RNA delivery
Aditya Raguram, Massachusetts Institute of Technology, Cambridge, Massachusetts - 9 a.m.
Adrian Krainer, Cold Spring Harbor Laboratory, Cold Spring Harbor, New York - 9:300 a.m. | Delivering on the promise of using microRNAs as anti-cancer agents*
Andrea Kasinski, Purdue University, West Lafayette, Indiana - 9:45 a.m. | Transformable supraclusters to reverse immune suppression and enhance stereotactic ablativeradio-immunotherapy*
Yuyan Jiang, Stanford University School of Medicine, Stanford, California
Break
10-10:30 a.m. | Evergreen Foyer
Plenary Session 5: RNAs as drivers and targets in cancer
10:30 a.m. – 12:30 p.m. | Evergreen E-F | CME Eligible
Session Chair: Josh Mendell, University of Texas Southwestern Medical Center, Dallas, Texas
- 10:30 a.m. | How codon content impacts mRNA stability and translation in mammalian cells
Josh Mendell - 11 a.m. | Long noncoding RNAs at the intersection of cancer pathways
Nadya Dimitrova, Yale University, New Haven Connecticut - 11:30 a.m.
Howard Chang, Stanford University, Stanford, California - 12 p.m. | mascRNA regulation of LARS-mTOR in breast cancer*
Erin Ahn, University of Alabama at Birmingham, Birmingham, Alabama - 12:15 p.m*
Mark Hatley, St. Jude Children’s Research Hospital, Memphis, Tennessee
Lunch Break (lunch on your own)
12:30-2:30 p.m.
Plenary Session 6: Small RNA therapeutics
2:30-4:30 p.m. | Evergreen E-F | CME Eligible
Session Chair: Anastasia Khvorova, University of Massachusetts Chan Medical School, Worcester, Massachusetts
- 2:30 p.m.
Anastasia Khvorova - 3 p.m.
Muthiah Manoharan, Alnylam Pharmaceuticals, Cambridge, Massachusetts - 3:30 p.m. | Antisense oligonucleotides as therapeutics for difficult-to-drug targets in oncology
Andrew Denker, Flamingo, Philadelphia, Pennsylvania - 4 p.m. | miR-590-3p nanomiRs inhibit rGBM growth*
Hernando Lopez-Bertoni, Johns Hopkins University School of Medicine, Baltimore, Maryland - 4:15 p.m. | A first-in-class EGFR-directed KRAS G12V inhibitor*
Lyla Stanland, EnFuego Therapeutics, Morrisville, North Carolina
Poster Session B (with light refreshments)
4:30-7 p.m. | Evergreen A-D
Continental Breakfast
7-8 a.m. | Evergreen A-D
Plenary Session 7: RNA for Cancer immunotherapy
8-10 a.m. | Evergreen E-F | CME Eligible
Session Chair: Crystal Mackall, Stanford University, Stanford, California
- 8 a.m. | RNA vaccines for pancreatic cancer
Vinod Balachandran, Memorial Sloan Kettering Cancer Center, New York, New York - 8:30 a.m.
Crystal Mackall - 9 a.m.
Grace Chen, Yale University, New Haven, Connecticut - 9:30 a.m. | Identification, therapeutic potential, and regulatory networks of tumor suppressing miRNAs in angiosarcoma*
Jason Hanna, Purdue University, West Lafayette, Indiana - 9:45 a.m. | PVT1 fusion on extrachromosomal DNA*
Hyerim Yi, Stanford University School of Medicine, Stanford, California
Break
10-10:30 a.m. | Evergreen Foyer
Plenary Session 8: Emerging RNA Technologies
10:30 a.m.- 12:30 p.m. | Evergreen E-F | CME Eligible
Session Chair: Xiaojing Gao, Stanford University, Stanford, California
- 10:30 a.m. | Programmable RNA sensors for internal states and external cues
Xiaojing Gao - 11 a.m.
Samantha Meyers, Scripps Research Institute/The Herbert Wertheim UF Scripps Institute for Biomedical Innovation & Technology, Jupiter, Florida - 11:30 a.m. RNA-targeted small molecule drug discovery, with atomic precision
Manjunath Ramarao, Atomic AI, Stanford, California - 12 p.m. | Decoding RNA metabolic networks by RNA-linked CRISPR screening in human cells*
Arvind Subramaniam, Fred Hutchinson Cancer Center, Seattle, Washington - 12:15 p.m. | Tool for profiling RNA modifications*
Norman Chiu, University of North Carolina at Greensboro, Greensboro, North Carolina
Closing Remarks
12:30-12:45 p.m.